NSCLC Clinical Trial - Study of Poziotinib in Japanese Patients With NSCLC

Status Terminated

Clinical Trial Summary

A Phase 1/2, open-label, multicenter study to determine dose, tolerability, safety and efficacy of poziotinib in Japanese patients non-small cell lung cancer (NSCLC).

Clinical Trial Description

This is a Phase 1/2, open-label, multicenter study in Japanese patients with locally advanced or metastatic NSCLC. This study will be conducted in two parts. Phase 1 is designed to observe the maximum tolerated dose (MTD) or maximum administered dose (MAD) of poziotinib when administered once daily or twice daily. Phase 2 will evaluate the safety and efficacy of the dose determined in Phase 1. Study participation includes a 30 day screening period, up to 24 months of treatment, and long-term follow-up for a maximum of 24 months after discontinuation of study treatment. Phase 1 will enroll up to 36 patients into a dose finding study with two parallel, randomized dose groups. Each group will undergo a dose-finding scheme using a 3+3 design with the assessment of dose-limiting toxicities (DLTs) at up to three dose levels. Patients will be randomized into once daily (QD) or twice daily (BID) dose groups. The DLT assessment will be conducted in the first cycle of treatment and therefore, poziotinib dose modifications are not permitted during this cycle. Patients will be hospitalized for the first 2 weeks. Phase 2 will enroll 40 additional NSCLC patients with EGFR (20 patients) or HER2 (20 patients) exon 20 insertion mutations. Efficacy and safety of the dose and dosing regimen determined in Phase 1 will be evaluated. All patients will be treated in 28-day cycles for up to 24 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04402008
Study type	Interventional
Source	Spectrum Pharmaceuticals, Inc
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	June 26, 2020
Completion date	May 15, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05821933` - RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC	Phase 1/Phase 2
Active, not recruiting	`NCT03269162` - Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection	Phase 3
Recruiting	`NCT05002270` - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation	Phase 1/Phase 2
Recruiting	`NCT06315686` - The Dynamic Monitoring of Cerebrospinal Fluid ctDNA	Phase 2
Active, not recruiting	`NCT05059522` - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing	Phase 3
Recruiting	`NCT05466149` - Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion	Phase 2
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 2
Completed	`NCT03609918` - Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
Recruiting	`NCT06043817` - First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations	Phase 1/Phase 2
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Recruiting	`NCT05078931` - A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients	Phase 2
Not yet recruiting	`NCT05547737` - Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
Not yet recruiting	`NCT05909137` - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Withdrawn	`NCT05959473` - EGFR_IUO 3.20 Clinical Study Protocol	N/A
Not yet recruiting	`NCT05005468` - A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.	Phase 2
Recruiting	`NCT01690390` - Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease	Phase 2
Completed	`NCT01852578` - Cabazitaxel in Relapsed and Metastatic NSCLC	Phase 2
Active, not recruiting	`NCT01460472` - Immunotherapy With Racotumomab in Advanced Lung Cancer	Phase 3
Completed	`NCT00702975` - Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy	Phase 2
Completed	`NCT00866970` - Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia	Phase 2